Clinical Trial

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2024 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-29; most recent amendment 2024-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06245629
Lead Sponsor Uppsala University
Collaborators: Uppsala County Council, Sweden, Dalarna County Council, Sweden
Conditions Myeloma Multiple
Enrollment 100 participants
Start Date 2024-11-24
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-29